Skip to main content

J&J Scores in a NJ Asbestos Linked Cancer Trial

J&J Scores in a NJ Asbestos Linked Cancer Trial

J&J Scores in a NJ Asbestos Linked Cancer Trial

Introduction

A New Jersey federal court on Thursday cleared Johnson & Johnson of a product liability case filed against it by a plaintiff. The deliberations went on for less than a day in New Brunswick, New Jersey, over allegations that asbestos presence in the company's talcum powder was the reason for her mesothelioma.

J&J faces more than 10,000 product liability cases across the U.S., all with the same assertion that the talcum giant knowingly concealed ovarian cancer and mesothelioma risks associated with its talc products. The company has been charged with cancer lawsuits for several years now. The first trial in April concluded with the jury verdict of $117 million to a man who suffered mesothelioma, and in May J&J was ordered to pay $25.7 million to a woman who was diagnosed with mesothelioma. Both these verdicts are currently under appeal. Four trials after that ended in mistrials as the jury declared a deadlock or because in some cases the plaintiffs passed away before the trial.  In July this year, a Missouri jury declared a massive verdict of $ 4.7 billion favoring 22 women who were diagnosed with ovarian cancer due to asbestos contamination in the talcum powder.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Second Valsartan Cancer Trials Set for Early 2026

Categories: Valsartan

As the first federal bellwether trial involving Valsartan cancer lawsuits approaches this fall, the U.S. District Judge overseeing the litigation has signaled that a…

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!